JP7860103B2 - 複素環式スピロ化合物及びその使用方法 - Google Patents

複素環式スピロ化合物及びその使用方法

Info

Publication number
JP7860103B2
JP7860103B2 JP2023524901A JP2023524901A JP7860103B2 JP 7860103 B2 JP7860103 B2 JP 7860103B2 JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023524901 A JP2023524901 A JP 2023524901A JP 7860103 B2 JP7860103 B2 JP 7860103B2
Authority
JP
Japan
Prior art keywords
amino
diazaspiro
methyl
octan
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023524901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549055A (ja
JP2023549055A5 (cg-RX-API-DMAC7.html
Inventor
ランマン,ブライアン・アラン
バナジー,アビシェク
チュウ-モイアー,マーガレット
ダイ,ドンチュン
カラー,マシュー・アール
ロペス,パトリシア
マー,ブー・バン
マノーニ,フランチェスコ
メディナ,ホセ・エム
ピックレル,アレクサンダー・ジェイ
タマヨ,ヌリア・エイ
ジュウ,カイ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023549055A publication Critical patent/JP2023549055A/ja
Publication of JP2023549055A5 publication Critical patent/JP2023549055A5/ja
Application granted granted Critical
Publication of JP7860103B2 publication Critical patent/JP7860103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023524901A 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法 Active JP7860103B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/123913 2020-10-27
CN2020123913 2020-10-27
PCT/US2021/056702 WO2022093856A1 (en) 2020-10-27 2021-10-26 Heterocyclic spiro compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2023549055A JP2023549055A (ja) 2023-11-22
JP2023549055A5 JP2023549055A5 (cg-RX-API-DMAC7.html) 2024-11-05
JP7860103B2 true JP7860103B2 (ja) 2026-05-15

Family

ID=78650109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524901A Active JP7860103B2 (ja) 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法

Country Status (7)

Country Link
US (1) US20230406860A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237086A1 (cg-RX-API-DMAC7.html)
JP (1) JP7860103B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021370660A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199082A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023004802A (cg-RX-API-DMAC7.html)
WO (1) WO2022093856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
AR128212A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
CN117186107A (zh) * 2022-05-31 2023-12-08 成都先导药物开发股份有限公司 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080540A1 (es) 2006-08-10 2008-06-08 Glaxo Group Ltd Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2019404576B2 (en) 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Also Published As

Publication number Publication date
US20230406860A1 (en) 2023-12-21
AU2021370660A1 (en) 2023-06-08
JP2023549055A (ja) 2023-11-22
CA3199082A1 (en) 2022-05-05
MX2023004802A (es) 2023-06-22
WO2022093856A1 (en) 2022-05-05
EP4237086A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
US20250059205A1 (en) Heterocyclic Compounds and Methods of Use
JP2024532735A (ja) 複素環式化合物及び使用方法
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
JP2024532734A (ja) 複素環式化合物及び使用方法
JP2025508703A (ja) キナゾリン化合物及びそれらの変異krasタンパク質の阻害剤としての使用
JP2024517693A (ja) 2-アミノベンゾチアゾール化合物及びその使用方法
AU2022219987A1 (en) Cdk inhibitors and methods of use thereof
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
AU2018201557A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
JP2016537384A (ja) ピロロピロロン誘導体およびbet阻害剤としてのその使用
CN105732637B (zh) 杂芳化合物及其在药物中的应用
US12534479B2 (en) Triazine compound and composition and use thereof
CN116249696B (zh) 嘧啶酮类化合物及其用途
CN117897159A (zh) 杂环化合物及使用方法
CN117835976A (zh) 杂环化合物及使用方法
CA3143350A1 (en) Small molecule inhibitors of nf-kb inducing kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260430

R150 Certificate of patent or registration of utility model

Ref document number: 7860103

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150